Ideagen PLC Issue of Equity (2183X)
December 17 2019 - 10:08AM
UK Regulatory
TIDMIDEA
RNS Number : 2183X
Ideagen PLC
17 December 2019
Ideagen PLC
("Ideagen," "the Company" or the "Group")
Issue of new shares under the Share Incentive Plan and Total
Voting Rights
Ideagen PLC (AIM: IDEA), a leading supplier of Information
Management Software to highly regulated industries, announces that
it has allotted a total of 4,291 new ordinary shares of 1 penny
each in the capital of the Company ("Ordinary Shares") following
the purchase of 4,291 Ordinary Shares by a number of employees
under the Company's Share Incentive Plan ("SIP").
Application has been made to the London Stock Exchange for the
4,291 new Ordinary Shares to be admitted to trading on AIM
("Admission") and it is expected that Admission will become
effective and trading will commence at 8.00 a.m. on 23 December
2019.
After Admission, the total number of Ordinary Shares in issue
will be 226,274,999 and the total number of voting rights will
therefore be 226,274,999. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
Enquiries:
Ideagen plc 01629 699100
David Hornsby, Executive Chairman
Ben Dorks, Chief Executive
Graeme Spenceley, Finance Director
finnCap Limited 020 7220 0500
Henrik Persson/James Thompson
(Nomad)
Alice Lane (ECM)
Canaccord Genuity 020 7523 8000
Simon Bridges
Richard Andrews
About Ideagen plc
Ideagen is a UK-headquartered, global technology company quoted
on the London Stock Exchange AIM market (Ticker: IDEA.L).
The Group provides IRM software and services to organisations
operating within highly regulated industries such as aviation,
banking and finance and life science, with its main operational
premises spread throughout the UK, EU, US, Middle East and SE
Asia.
With an excellent portfolio of software products including
Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its
clients reduce costs, improve operational efficiency, strengthen
compliance and oversight and anticipate and manage every detail of
risk.
Currently, more than 4,700 organisations use Ideagen's products
including seven of the top 10 UK accounting firms, all of the top
aerospace and defence companies and 75% of the world's leading
pharmaceutical firms.
Ideagen's diverse and varied customer base includes many
well-known, global brands such as British Airways, Aggreko, BAE,
Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank,
Meggitt, Heineken, Johnson Matthey, Haeco Group and European
Central Bank. As well as this, Ideagen counts 180 hospitals across
the UK and US amongst its client base.
For further information please visit www.ideagen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEBLBDDRGBBGCR
(END) Dow Jones Newswires
December 17, 2019 11:08 ET (16:08 GMT)
Ideagen (LSE:IDEA)
Historical Stock Chart
From Apr 2024 to May 2024
Ideagen (LSE:IDEA)
Historical Stock Chart
From May 2023 to May 2024